

Swissmedic, Swiss Agency for Therapeutic Products

Report No: *CH19-1336*

STATEMENT OF NON-COMPLIANCE WITH GMP

Exchange of information between National Competent Authorities (NCAs) of the EEA following the discovery of serious GMP non-compliance at a manufacturer

Part 1

Issued under the provisions of the Mutual Recognition Agreement between the European Union and *Switzerland*

The competent authority of Switzerland confirms the following:

The manufacturer: *ACHARYA CHEMICALS*

Site address: *W41 & W42, MIDC Industrial estate - Morivali Village, 421501 AMBARNATH (W) (Dist Thane), 42150, India*

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on *2019-10-09*, it is considered that **it does not comply with the Good Manufacturing Practice** requirements referred to in

The Good Manufacturing Practice requirements referred to in the Agreement of Mutual Recognition between the European Union and *Switzerland*

Part 2

Human Medicinal Products

1 NON-COMPLIANT MANUFACTURING OPERATIONS

Include total and partial manufacturing (including various processes of dividing up, packaging or presentation), batch release and certification, storage and distribution of specified dosage forms unless informed to the contrary;

1.4	Other products or manufacturing activity
	1.4.3 Other: <i>Manufacture of Active Substances(en)</i>

Manufacture of active substance. Names of substances subject to non-compliant :

METRONIDAZOLE BENZOATE PH. EUR.(en)

AMLODIPINE BESILATE(en)

CETIRIZINE DIHYDROCHLORIDE(en)

3. NON-COMPLIANT MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

Active Substance : METRONIDAZOLE BENZOATE PH. EUR.

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.3 Salt formation / Purification steps : benzoate formation and crystallisation
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing

Active Substance : AMLODIPINE BESILATE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing

Active Substance : CETIRIZINE DIHYDROCHLORIDE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing

Part 3

1. Nature of non-compliance:

During the joint Swissmedic / EDQM Inspection 2 critical, 3 major and 14 other deficiencies were identified. The company failed in its multipurpose facility to mitigate the risk of cross- contamination and was not aware of the measures to be taken before introducing a new chemical entity in the synthesis area. A lack of effective maintenance and rust and dirt in hardly cleanable premises were obvious. The recovery of solvent in-house and partially outsourced to a distillation contract-acceptor plant was not properly managed and caused therefore a risk for the health of human and veterinary patients. The not qualified and adequate monitored storage area of raw materials could be a risk for the Metronidazole starting material due to the not justified storage condition. The change of the computerised system in the QC laboratory showed several shortcomings. The firm's quality management system did not prevent the reworking of batches subject to regulatory filings without prior approval by relevant agencies. This became evident when reworking as follow-up of an OOS-result for impurity A (Metronidazole) in final API Metronidazole benzoate was identified. The identified critical and major deviations pose a risk for all manufactured Intermediates and APIs in the multipurpose plant.

Action taken/proposed by the NCA**Suspension or voiding of CEP (action to be taken by EDQM)**

The CEP 2007-056 / Metronidazole benzoate will be suspended based on the negative outcome of this inspection. Acharya Chemicals will be removed as intermediate manufacturer from CEP 2002-072 / Amlodipine besilate and CEP 2003-171 / Cetirizine dihydrochloride based on the negative outcome of this inspection.

2019-11-21

Name and signature of the authorised person of the
Competent Authority of Switzerland

Confidential

Swissmedic, Swiss Agency for Therapeutic Products

Tel: *Confidential*

Fax: *Confidential*